Statin therapy for Alzheimer's disease. Will it work?

Journal of Molecular Neuroscience

Volumn 19, Issue 1-2, 2002, Pages 155-161

  Petanceska, S S ^a   DeRosa, S ^a   Olm, V ^a   Diaz, N ^a   Sharma, A ^a   Thomas Bryant, T ^b   Duff, K ^a   Pappolla, M ^b   Refolo, L M ^c  

^a NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^b UNIVERSITY OF SOUTH ALABAMA   (United States)

^c Alzheimers Drug Discovery Foundation   (United States)

Author keywords

Amyloid; Animal model; Cholesterol; Statin; Therapy

Indexed keywords

AMYLOID BETA PROTEIN; ATORVASTATIN; BIOLOGICAL MARKER; CHOLESTEROL; FLUINDOSTATIN; HYPOCHOLESTEROLEMIC AGENT; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; STATINE DERIVATIVE;

ALZHEIMER DISEASE; AMYLOIDOSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FEMALE; MALE; MOUSE; NONHUMAN; PROTEIN CONTENT; TRANSGENIC MOUSE;

ANIMALIA; MUS MUSCULUS;

EID: 0036672689     PISSN: 08958696     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12031-002-0026-2     Document Type: Article

References (31)

1. Inflammation and Alzheimer's disease
2. Cholesterol modulates alpha-secretase cleavage of amyloid precursor protein
3. Statins: Effective antiatherosclerotic therapy
4. Use of statins in CNS disorders
5. Serum cholesterol, APOE genotype, and the risk of Alzheimer's disease: A population-based study of African Americans
6. Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo
7. The role of cholesterol in the biosynthesis of beta-amyloid
8. Treatment with controlled-release lovastatin decreases serum concentrations of human beta-amyloid (A beta) peptide
9. Hydrophilicity/lipophilicity: Relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors
10. Modulation of secreted beta-amyloid precursor protein and amyloid beta-peptide in brain by cholesterol
11. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes
12. Genetics of Alzheimer's disease
13. Genetic influences on age-related change in total cholesterol, low-density lipoprotein-cholesterol, and triglyceride levels: Longitudinal apolipoprotein E genotype effects
14. Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer's disease: A case-control study
15. Statins and the risk of dementia
16. Dietary fat intake and the risk of incident dementia in the Rotterdam Study
17. Current perspectives on statins
18. Cholesterol-dependent generation of a unique amyloid beta-protein from apically missorted amyloid precursor protein in MDCK cells
19. Clinical pharmacology of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors
20. Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease
21. Acylcoenzyme A: Cholesterol acyltransferase modulates the generation of the amyloid beta-peptide
22. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model
23. A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease
24. Amyloid and lipids in the pathology of Alzheimer disease
25. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons
26. Induction of Alzhemier's-like beta-amyloid immunoreactivity in brains of rabbits with dietary cholesterol
27. Coronary artery disease, hypertension, ApoE, and cholesterol: A link to Alzheimer's disease?
28. Link between heart disease, cholesterol, and Alzheimer's disease: A review
29. Plasma levels of amyloid beta proteins did not differ between subjects taking statins and those not taking statins
30. Decreased prevalence of Alzheimer's disease associated with 3-hydroxy3-methylglutaryl coenzyme A reductase inhibitors
31. A fluid connection: Cholesterol and Abeta